По вашему запросу найдено документов: 34

Страница 1 из 4

Therapeutic drug monitoring (TDM) as intervention: A cross-sectional analysis of characteristics of 173 registered clinical trials
Zhao, Shanshan, Zaytseva, Olga, Zaytseva, Olga, Zhang, Boquan (2022)
Background: To examine fundamental characteristics of clinical trials with therapeutic drug
Phase I/II trial of local interstitial chemotherapy with arsenic trioxide in patients with newly diagnosed glioma
Han, Dayong, Teng, Lei, Wang, Xiaoxiong, Zhen, Yunbo, Chen, Xiaofeng, Yang, Mingchun, Gao, Ming, Yang, Guang, Han, Mingyang, Wang, Ligang, Xu, Jiajun, Li, Yue, Shumadalova, Alina, Zhao, Shiguang (2022)
, and the dose recommended for a phase II trial is 1.5 mg. Copyright © 2022 Han, Teng, Wang, Zhen, Chen, Yang
Safety and Efficacy of Lonapegsomatropin in Children With Growth Hormone Deficiency: enliGHten Trial 2-Year Results
Maniatis, AK;, Casella, SJ;, Nadgir, UM;, Hofman, PL;, Saenger, P;, Chertock, ED;, Aghajanova, EM;, Korpal-Szczyrska, M;, Vlachopapadopoulou, E;, Malievskiy, O;, Chaychenko, T;, Cappa, M;, Song, WJ;, Mao, M;, Mygind, PH;, Smith, AR;, Chessler, S;, Komirenko, AS;, Beckert, M;, Aimee, D Shu, Paul, S Thornton (2022)
Purpose: The objectives of the ongoing, Phase 3, open-label extension trial enliGHten are to assess
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
Onorato, Eustaquio Maria, Onorato, Eustaquio Maria, Muratori, Manuela, Smolka, Grzegorz, Wojakowski, Wojtek, Pysz, Piotr, Zorinas, Aleksejus, Zakarkaite, Diana, Eltchaninoff, Hélène, Litzer, Pierre-Yves, Godart, François, Calvert, Patrick, Christou, Christos, Mussayev, Abdurashid, Missiroli, Bindo, Buzaev, Igor, Curello, Salvatore, Tesorio, Tullio, Bartorelli, Antonio Luca (2022)
deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
Kristeleit, Rebecca, Lisyanskaya, Alla, Fedenko, Alexander, Dvorkin, Mikhail, de Melo, Andreia Cristina, Shparyk, Yaroslav, Rakhmatullina, Irina, Bondarenko, Igor, Colombo, Nicoletta, Svintsitskiy, Valentyn, Biela, Luciano, Nechaeva, Marina, Lorusso, Domenica, Scambia, Giovanni, Cibula, David, Póka, Róbert, Oaknin, Ana, Safra, Tamar, Mackowiak-Matejczyk, Beata, Ma, Ling, Thomas, Daleen, Lin, Kevin K, McLachlan, Karen, Goble, Sandra, Oza, Amit M (2022)
dose of assigned study treatment. This study is registered with ClinicalTrials.gov, NCT02855944
Роль неоадъювантной гормонотерапии в лечении рака молочной железы: что мы знаем на данный момент?
Preoperative Hormone Therapy in the Treatment of Breast Cancer: What Do We Know So Far?
В. В. Воротников, V. V. Vorotnikov, Р. А. Пахомова, R. A. Pakhomova, А. В. Сойнов, A. V. Soinov, А. С. Гунина, A. S. Gunina, И. В. Копытич, I. V. Kopytich, М. Г. Цой, M. G. Tsoi, С. А. Абдугаффоров, S. A. Abdugafforov (Креативная хирургия и онкология, №3, 2022)
Therapeutic effect of natural polyphenols against glioblastoma
Beylerli, Ozal, Beilerli, Aferin, Shumadalova, Alina, Wang, Xiaoxiong, Yang, Mingchun, Sun, Hanran, Teng, Lei (2022)
of glioblastoma. However, clinical trials are still needed to confirm the properties of these compounds in vitro
The risk of tumor with the use of recombinant human bone morphogenetic proteins
Mukhametov, U.F., Lyulin, S.V., Borzunov, D.Yu., Sufianov, R.A., Gareev, I.F. (2022)
clinical trials in a wide population over a longer timeframe © Mukhametov U.F., Lyulin S.V., Borzunov D
Improvement of brain perfusion in patients with chronic brain ischemia at epidural spinal cord electrical stimulation
Zhao, S., Sufianova, G., Shapkin, A., Mashkin, A., Meshcheryakova, S., Han, DY (2022)
at the cervical (C3-C5) and lower thoracic (Th9-Th10) levels. Results: In all patients, on the 5th day of trial
Circulating miRNAs as Diagnostic and Prognostic Biomarkers in High-Grade Gliomas
Wu, JN, Al-Zahrani, A, Beylerli, O, Sufianov, R, Talybov, R, Meshcheryakova, S, Sufianova, G, Gareev, I, Sufianov, A (2022)
Central Register of Controlled Trials, and Web of Science database and obtained different sets of data

Страница 1 из 4

Google Scholar
OpenDoar

Фасеты

Авторы
Ключевые слова
Год